Research programme: cancer and diabetes therapeutics - Evotec/Sanofi

Drug Profile

Research programme: cancer and diabetes therapeutics - Evotec/Sanofi

Alternative Names: EVT 601; EVT 701; EVT 801; TargetBCD

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Evotec AG; Sanofi
  • Class Cell therapies; Small molecules
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Diabetes mellitus

Most Recent Events

  • 16 Aug 2016 Preclinical trials in Cancer in France (unspecified route) (EVOTEC pipeline - August 2016)
  • 16 Aug 2016 Preclinical trials in Cancer in Germany (unspecified route) (EVOTEC pipeline - August 2016)
  • 16 Aug 2016 Evotec and Sanofi plan a phase I trial for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top